舒利迭和信必可都保治疗慢性阻塞性肺疾病的临床对照研究  

A clinical controlled research of Seretide and Symbicort Turbuhaler in the treatment of chronic obstructive pulmonary disease

作　　者：吴超[1] 孙明[1] WU Chao;SUN Ming(Emergency Center,Nanjing Gulou Hospital Group Suqian People’s Hospital,Suqian 223800,China)

机构地区：[1]南京鼓楼医院集团宿迁市人民医院急诊中心,223800

出　　处：《中国现代药物应用》2018年第18期1-3,共3页Chinese Journal of Modern Drug Application

摘　　要：目的评价沙美特罗替卡松粉吸入剂(商品名:舒利迭)和布地奈德福莫特罗粉吸入剂(商品名:信必可都保)治疗慢性阻塞性肺疾病的临床疗效和安全性。方法 68例慢性阻塞性肺疾病患者,随机分为舒利迭组和信必可都保组,各34例。舒利迭组吸入舒利迭,信必可都保组吸入信必可都保,比较两组患者临床疗效。结果两组患者治疗前第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1占用力肺活量百分比(FEV1/FVC)比较,差异均无统计学意义(P>0.05);吸入后10 min,信必可都保组患者的FEV1、FVC、FEV1/FVC均明显优于舒利迭组,差异均具有统计学意义(P<0.05);吸入后1 h,两组患者的FEV1、FVC、FEV1/FVC比较差异无统计学意义(P>0.05);吸入后12 h,舒利迭组患者的FEV1、FVC、FEV1/FVC均明显优于信必可都保组,差异均具有统计学意义(P<0.05)。治疗后随访6个月,舒利迭组急性加重发生率为32.4%(11/34),信必可都保组为26.5%(9/34),比较差异无统计学意义(P>0.05)。舒利迭组出现4例心悸,2例震颤,信必可都保组出现2例心悸,3例震颤,2例口干、咽部不适,比较差异无统计学意义(P>0.05)。结论舒利迭和信必可都保对慢性阻塞性肺疾病的症状和肺功能都有良好的改善作用,信必可都保起效更迅速,舒利迭维持时间较信必可都保更长。Objective To evaluate the clinical efficacy and safety of Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation(trade name:Seretide)combined with Budesonide and Formoterol Fumarate Powder for inhalation(trade name:Symbicort Turbuhaler)in the treatment of chronic obstructive pulmonary disease.Methods A total of 68 patients with chronic obstructive pulmonary disease were randomly divided into Seretide group and Symbicort Turbuhaler group,34 cases in each group.The Seretide group was given Seretide for inhalation,the Symbicort Turbuhaler group was given Symbicort Turbuhaler for inhalation.The clinical efficacy of the two groups were compared.Results There were no significant differences in forced expiratory volume in 1st second(FEV1),forced vital capacity(FVC)and ratio of forced expiratory volume in 1st second to forced vital capacity(FEV1/FVC)between the two groups before treatment(P>0.05).After 10 min of inhalation,the FEV1,FVC and FEV1/FVC in Symbicort Turbuhaler group were significantly better than those in the Seretide group,the differences were statistically significant(P<0.05).After inhalation of 1 h,there were no significant differences in the FEV1,FVC and FEV1/FVC between the two groups(P>0.05).After 12 h of inhalation,the FEV1,FVC and FEV1/FVC in Seretide group were significantly better than those in the Symbicort Turbuhaler group,the differences were statistically significant(P<0.05).After 6 months of follow-up,the incidence of acute exacerbation in Seretide group was 32.4%(11/34),and that in Symbicort Turbuhaler group was 26.5%(9/34),there was no statistically significant difference(P>0.05).There were 4 cases of palpitations,2 cases of tremor in Seretide group,there were 2 cases of palpitations,3 cases of tremor,2 cases of dry mouth and pharyngeal discomfort in the Symbicort Turbuhaler group,the difference was not statistically significant(P>0.05).Conclusion Both Seretide and Symbicort Turbuhaler have good improvement effects on the symptoms and pulmonary function of chronic obstructive p

关 键 词：沙美特罗替卡松粉吸入剂 布地奈德福莫特罗粉吸入剂 慢性阻塞性肺疾病 肺功能 

分 类 号：R563.9[医药卫生—呼吸系统]